The role of the adenosinergic system in lung fibrosis

Pharmacological Research

Volumn 76, Issue , 2013, Pages 182-189

  Della Latta, Veronica ^a,b   Cabiati, Manuela ^a   Rocchiccioli, Silvia ^a   Del Ry, Silvia ^a   Morales, Maria Aurora ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Adenosine; Adenosine receptors; Bleomycin; Idiopathic pulmonary fibrosis; Lung disease

Indexed keywords

ACETYLCYSTEINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMATINIB; PIRFENIDONE; PREDNISOLONE; STEROID;

AIRWAY REMODELING; ARTICLE; BINDING AFFINITY; BRONCHOSPASM; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FIBROSING ALVEOLITIS; GENOTYPE ENVIRONMENT INTERACTION; HOMEOSTASIS; HUMAN; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; MOLECULAR INTERACTION; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURINE METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC ORGANISM;

3-ETHYL-5-BENZYL-2-METHYL-4-PHENYLETHYNYL-6-PHENYL-1,4-(±)-DIHYDROPYRIDINE-3,5-DICARBOXYLATE; 3-PROPYL-6-ETHYL-5-[(ETHYLTHIO)CARBONYL]-2-PHENYL-4-PROPYL-3-PYRIDINECARBOXYLATE; 4-(2-[7-AMINO-2-(2-FURYL)-{1,2,4}-TRIAZOLO{2,3-A}{1,3,5}TRIAZIN-5-YLAMINO]ETHYL)PIENO; 5-[[(4-METHOXYPHENYL)AMINO]CARBONYL]AMINO-8-METHYL-2-(2-FURYL)PYRA-ZOLO[4,3-E]1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE; 8-[4-[[[[(2-AMINOETHYL)AMINO]CARBONYL]METHYL]OXY]PHENYL]-L,3-DIPROPYLXANTHINE; 1-DEOXY-1,6[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9YL-N-METHYL-B-D-RIBOFURONAMIDE; 1-PROPYL-8-P-SULFOPHENULXANTHINE; 2 HEXYNYL-5′-N ETHYLCARBOXAMIDOADENOSINE; 2-(2-PHENYL)ETHYNYL-N-ETHYLCARBOXAMIDO-ADENOSINE; 2-CHLORO-N6-CYCLOPENTYLADENOSINE; 2-CI-IB MECA; 2-CLORO-N6-(3-IODOBENZYL)-ADENOSINE-50-N METHYLURONAMIDE; 2-METHYL-6-PHENYL-4-PHENYLETHYNYL-1,4-DIHYDRO-PYRIDINE-3,5-DICARBOXYLICACID-3-ETHYL ESTER-5-(4-NITRO-BENZYL)ESTER; 2-P-(2-CARBOXYETHYL) PHENETHYLAMINO-50-N-ETHYL-CARBOXAMIDOADENOSINE; 2-PHENYL HYDROXYPROPYNYL-5′-N-ETHYLCARBOXAMIDO ADENOSINE PHOSPHOINOSITIDE 3; 3-ETHYL-1-PROPYL-8-(1-(3-(TRIFLUOROMETHYL) BENZYL)-1H-PYRAZOL-4-YL)-1H-PURINE-2,6(3H,7H)-DIONE; 7-METHYL-[11C]-(E)-8-(3-BROMOSTYRYL)-3,7-DIMETHYL-1-PROPARGYLXANTHIN; 8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE; 9-CHLORO-2-(2-FURANYL)-5-[(PHENYLACETYL) AMINO] [1,2,4]-TRIAZOLO[1,5-C]QUINAZOLINE; 9-CHLORO-2-(2-FURANYL)-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE; A(1)R; A(2A)R; A(2B)R; A(3)R; AB-MECA; ACUTE INTERSTITIAL PNEUMONIA; ADA; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE KINASE; ADENOSINE MONOPHOSPHATE; ADENOSINE RECEPTORS; ADENOSINE TRIPHOSPHATE; ADO; ADORA 1 RECEPTOR; ADORA 2A RECEPTOR; ADORA 2B RECEPTOR; ADORA 3 RECEPTOR; ADP; AIP; AK; AMP; ARS; ATP; BLEOMYCIN; CAMP; CCPA; CD39; CD73; CENTRAL NERVOUS SYSTEM; CGS 15943; CGS21680; CHA; CHRONIC OBSTRUCTIVE PULMONARY DISEASES; CNS; CNT-1; CNT-2; CONCENTRATIVE NUCLEOSIDE TRANSPORTERS-1; CONCENTRATIVE NUCLEOSIDE TRANSPORTERS-2; COP; COPD; CPA; CRYPTOGENIC ORGANIZING PNEUMONIA; CVT6883; CYCLIC ADENOSINE MONOPHOSPHATE; DAG; DESQUAMATIVE INTERSTITIAL PNEUMONIA; DIACYLGLYCEROL; DIP; DPCPX; E-8-(3,4-DIMETHOXYSTYRYL)-1,3-DIPROPYL-7-METHYLXANTHINE; ECM; ECTO-5′-NUCLEOTIDASE; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; ENDOTHELIN 1; ENT-1; ENT-2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS-1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTERS-2; ET-1; EXTRACELLULAR MATRIX; FITC; FLUORESCEIN ISOTHIOCYANATE; HE-NECA; IB-MECA; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; IIPS; ILD; INO; INOSINE; INTERSTITIAL LUNG DISEASE; IPF; KF17837; LIP; LUNG DISEASE; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; MAP; MITOGEN-ACTIVATED PROTEIN; MRE3008-F207; MRS 1191; MRS 1220; MRS 1334; MRS 1523; MRS 1754; N-(4-CYANOPHENYL)-2-[4-(2,3,6,7-TETRAHYDRO-2,6-DIOXO-1,3-DIPROPYL-1H-PURIN-8-YL)-PHENOXY]ACETAMIDE; N-ETHYLCARBOXAMIDO-ADENOSINE; N6-(2-PHENYLISOPROPYL)ADENOSINE; N6-(4-AMINOBENZYL)-ADENOSINE-5′-N-METHYLURONAMIDEDIHYDROCHLORIDE; N6-CYCLOHEXYL ADENOSINE; N6-CYCLOPENTYLADENOSINE; NECA; NONSPECIFIC INTERSTITIAL PNEUMONIA; NSPI; PAH; PENECA; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PHOSPHOLIPASE D; PHPNECA; PIA; PKC; PLA2; PLC; PLD; PROTEIN KINASE C; PSB1115; PULMONARY ARTERIAL HYPERTENSION; RB-ILD; REACTIVE OXYGEN SPECIE; RESPIRATORY BRONCHIOLITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE; ROS; SCH-58261; UIP; USUAL INTERSTITIAL PNEUMONIA; XAC; ZM 241385; [11C]BS-DMPX; [7-(2-PHENYLETHYL)-5-AMINO-2-(2-FURYL)-PYRAZOLO-(4,3-E)-1,2,4-TRIAZOLO(1,5-C) PYRIMIDINE];

ADENOSINE; ANIMALS; HUMANS; LUNG; MICE; PULMONARY FIBROSIS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 84883859802     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.08.004     Document Type: Review

References (67)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias Am J Respir Crit Care Med 165 2001 277 304
2. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement Am J Respir Crit Care Med 161 2000 646 664
3. C.K. Oh, L.A. Murray, and N.A. Molfino Smoking and idiopathic pulmonary fibrosis Pulm Med 2012
4. G. Raghu, T.D. Freudenberger, S. Yang, J.R. Curtis, C. Spada, and J. Hayes High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis Eur Respir J 27 2006 136 142 (Pubitemid 43092677)
5. P.J. Sime, and K.M.A. O'Reilly Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment Clin Immunol 99 2001 308 319
6. G. Hasko, J. Linden, B. Cronstein, and P. Pacher Adenosine receptors: therapeutic aspects for inflammatory and immune diseases Nat Rev 7 September 2008
7. B.N. Cronstein Adenosine receptors and fibrosis: a translational review F1000 Biol Rep 3 2011 21
8. A. Antonioli, M. Fornai, R. Colucci, N. Ghisu, M. Tuccori, and M. Del Tacca Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases Inflamm Bowel Dis 14 2008 566 574 (Pubitemid 351571838)
9. Y. Zhou, D.J. Schneider, and M.R. Blackburn Adenosine signaling and the regulation of chronic lung disease Pharmacol Ther 123 2009 105 116
10. G. Hasko, and B.N. Cronstein Adenosine: an endogenous regulator of innate immunity Trends Immunol 25 2004 33 39 (Pubitemid 38032805)
11. Y. Zhou, J.N. Murthy, D. Zeng, L. Belardinelli, and M.R. Blackburn Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis PLoS ONE 5 2 2010 e9224
12. S. Sachdeva, and M. Gupta Adenosine and its receptors as therapeutic targets: an overview Pharm J 2012 10.1016/j.jsps.2012.05.011
13. S. Del Ry, M. Cabiati, V. Lionetti, G.D. Aquaro, A. Martino, and L. Mattii Pacing-induced regional differences in adenosine receptors mRNA expression in a swine model of dilated cardiomyopathy PLoS ONE 7 10 2012 e4701
14. B.B. Freedholm Adenosine an endogenous distress signal, modulates tissue damage and repair Cell Death Differ 14 2007 1315 1323
15. H. Karmouty-Quintana, Y. Xia, and M.R. Blackburn Adenosine signaling during acute and chronic disease states J Mol Med 91 2013 173 181
16. G. Burnstock Purine and pyrimidine receptors Cell Mol Life Sci 64 2007 1471 1483 (Pubitemid 46954150)
17. V. Ralevic, and G. Burnstock Receptors for purines and pyrimidines Pharmacol Rev 50 1998 413 492 (Pubitemid 28477681)
18. B.B. Freedholm, A.P. Ljzerman, K.A. Jacobson, K.N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol Rev 53 2001 527 552 (Pubitemid 33136237)
19. S. Del Ry, M. Cabiati, A. Martino, A. Simioniuc, M-A. Morales, and E. Picano Adenosine receptor mRNA expression in normal and failing minipig Hearts J Cardiovasc Pharmacol 58 2011 149 156
20. B.B. Freedholm, G. Arslan, L. Halldner, B. Kull, G. Schulte, and W. Wasserman Structure and function of adenosine receptors and their genes Naunyn-Schmiedeberg's Arch Pharmacol 362 2000 364 374
21. J. Linden Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection Annu Rev Pharmacol Toxicol 41 2001 775 787 (Pubitemid 32385906)
22. K-N. Klotz Adenosine receptors and their ligands Naunyn-Schmiedeberg's Arch Pharmacol 362 2000 382 391
23. C. Victor-Vega, A. Desai, M.C. Montesinos, and B.N. Cronstein Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin Gel) Inflammation 26 2002 19 24 (Pubitemid 34226179)
24. S. Moro, Z-G. Gao, K.A. Jacobson, and G. Spalluto Progress in the pursuit of therapeutic adenosine receptor antagonists Med Res Rev 26 2005 131 159
25. S. Hess, C.E. Müller, W. Frobenius, U. Reith, K-N. Klotz, and K. Eger 7-Deazaadenines bearing polar substituents: structure-activity relationships of new A1 and A3 adenosine receptor antagonists J Med Chem 43 2000 4636 4646
26. J.E. van Muijlwijk-Koezen, H. Timmerman, R.C. Vollinga, J. Frijtag von Drabbe Künzel, M. de Groote, and S. Visser Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists J Med Chem 44 2001 749 762 (Pubitemid 32171671)
27. C.E. Müller, U. Geis, J. Hipp, U. Schobert, W. Frobenius, and M. Pawłowski Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists J Med Chem 40 1997 4396 4405 (Pubitemid 28042319)
28. M. Demedts, A.U. Wells, J.M. Anto, U. Costabel, R. Hubbard, and P. Cullinan Interstitial lung diseases: an epidemiological overview Eur Respir J 18 Suppl. 32 2001 2s 16s (Pubitemid 34755182)
29. T.J. Gross, and G.W. Hunninghake Idiophatic pulmonary fibrosis N Engl J Med 345 2001 517 525
30. V.J. Thannickal, G.B. Toews, E.S. White, J.P. Lynch III, and F.J. Martinez Mechanisms of pulmonary fibrosis Annu Rev Med 55 2004 395 417 (Pubitemid 38316734)
31. D.S. Kim, H.R. Collard, and T.E. King Classification and natural history of the idiopathic interstitial pneumonias Proc Am Thorac Soc 3 2006 285 292 (Pubitemid 43845404)
32. K.B. Baumgartner, J.M. Samet, D.B. Coultas, C.A. Stidley, W.C. Hunt, and T.V. Colby Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study Am J Epidemiol 152 2000 307 315 (Pubitemid 30626724)
33. V.S. Taskar, and D.B. Coultas Is idiopathic pulmonary fibrosis an environmental disease Proc Am Thorac Soc 3 2006 293 298 (Pubitemid 43845405)
34. A. Pardo, and M. Selman Molecular mechanisms of pulmonary fibrosis Front Biosci 7 2002 d1743
35. J.L. Chunn, A. Mohsenin, H.W.J. Young, C.G. Lee, J.A. Elias, and R.E. Kellems Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations Am J Physiol Lung Cell Mol Physiol 290 2006 L579 L587
36. J.L. Chunn, J.G. Molina, T. Mi, Y. Xia, R.E. Kellems, and M.R. Blackburn Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice J Immunol 175 2005 1937 1946 (Pubitemid 41023101)
37. M. Selman, and A. Pardo Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder Respir Res 3 2002 3
38. M. Selman, T.E. King, and A. Pardo Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy Ann Intern Med 134 2001 136 151 (Pubitemid 32096342)
39. C.J. Scotton, and R.C. Chambers Molecular targets in pulmonary fibrosis. The Myofibroblast in Focus Chest 132 2007 1311 1321 (Pubitemid 47621009)
40. M. Caruso, A. Alamo, E. Crisafulli, C. Raciti, A. Fisichella, and R. Polosa Adenosine signaling pathways as potential therapeutic targets in respiratory disease Expert Opin Ther Targets 17 2013 761 772
41. M. Caruso, S.T. Holgate, and R. Polosa Adenosine signalling in airways Curr Opin Pharmacol 6 2006 251 256 (Pubitemid 43670912)
42. M.J. Cuschley, A.E. Tattersfield, and S.T. Holgate Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects Br J Clin Pharmacol 15 1983 161 165 (Pubitemid 13184390)
43. L. Spicuzza, G. Di Maria, and R. Polosa Adenosine in the airways: implications and applications Eur J Pharmacol 533 2006 77 88 (Pubitemid 43340006)
44. E. Morschl, J.G. Molina, J.B. Volmer, A. Mohsenin, R.S. Pero, and J-S. Hong A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis Am J Respir Cell Mol Biol 39 2008 697 705
45. G. Burnstock, I. Brouns, D. Adriaense, and J.-P. Timmermans Purinergic signaling in the airways Pharmacol Rev 64 2012 834 868
46. C.X. Sun, H.W. Young, J.G. Molina, J.B. Volmer, J. Schnermann, and M.R. Blackburn A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury J Clin Invest 115 1 2005 35 43 (Pubitemid 40385503)
47. H. Zhong, L. Belardinelli, T. Maa, and D. Zeng Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts Am J Respir Cell Mol Biol 32 2005 2 8 (Pubitemid 40053298)
48. C-X. Sun, H. Zhong, A. Mohsenin, E. Morschl, J.L. Chunn, and J.G. Molina Role of the A2B adenosine receptor signaling in adenosine dependent pulmonary inflammation and injury J Clin Invest 116 8 2006 2173 2182 (Pubitemid 44162326)
49. Y. Zhou, D.J. Schneider, E. Morschl, L. Song, M. Pedroza, and H. Karmounty-Quintana Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury J Immunol 186 2011 1097 1106
50. H. Zhong, Y. Wu, L. Belardinelli, and D. Zeng A2B adenosine receptors induce IL-19 from bronchial epithelial cells and results in TNF-{alpha} increase Am J Respir Cell Mol Biol 35 5 2006 587 592 (Pubitemid 44706432)
51. J. Araya, and S.L. Nishimura Fibrogenic reactions in lung disease Annu Rev Pathol Mech Dis 5 2010 77 98
52. N.W. Todd, I.G. Luzina, and S.P. Atamas Molecular and cellular mechanisms of pulmonary fibrosis Fibrogenesis Tissue Repair 5 2012 11
53. H. Karmounty-Quintana, H. Zhong, L. Acero, T. Weng, E. Melicoff, and J.D. West The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease FASEB J 26 2012 2546 2557
54. K.A. Scherinbner, S. Boodoo, S. Collins, K.E. Black, Y. Chan-Li, and P. Zarek The adenosine A2a receptor inhibits matrix-induced inflammation in a novel fashion Am J Respir Cell Mol Biol 40 2009 251 259
55. B.B. Moore, and C.M. Hogaboam Murine models of pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol 294 2008 L152 L160
56. A.L. Degryse, and W.E. Lawson Progress toward improving animal models for IPF Am J Med Sci 341 2011 444 449
57. D.M. Walters, and S.R. Kleeberger Mouse models of bleomycin-induced pulmonary fibrosis Curr Protoc Pharmacol 2008
58. A. Serrano-Mollar, D. Closa, N. Prats, S. Blesa, M. Martinez-Losa, and J. Cortijo In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats Br J Pharmacol 138 2003 1037 1048 (Pubitemid 36459826)
59. N.R. Grande, M.N.D. Peão, C.M. de Sá, and A.P. Águas Lung fibrosis induced by bleomycin: structural changes and overview of recent advances Scan Microsc 12 1998 487 494
60. E. Fireman A silica-induced pulmonary fibrosis model: are we closer to 'real life'? Int Arch Allergy Immunol 158 2012 211 212
61. V. Barbarin, A. Nihoul, P. Misson, M. Arras, M. Delos, and I. Leclercq The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis Respir Res 6 2005 112
62. P.J. Christensen, R.E. Goodman, L. Pastoriza, B. Moore, and G.B. Toews Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent Am J Pathol 155 1999 1773 1779
63. G.W. Morgan, B. Pharm, and S.N. Breit Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury Int J Radiat Oncol Biol Phys 31 1995 361 369
64. Y. Miyazaki, K. Araki, C. Vesin, I. Garcia, Y. Kapanci, and J.A. Whitsett Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis J Clin Invest 96 1995 250 259
65. O.J. O'Connell, M.P. Kennedy, and M.T. Henry Idiopathic pulmonary fibrosis: treatment update Adv Ther 28 2011 986 999
66. S. Park, and E.J. Lee Recent advances in idiopathic pulmonary fibrosis Tuberc Respir Dis 74 2013 1 6
67. R.M. Du Bois Strategies for treating idiopathic pulmonary fibrosis Nat Rev Drug Discov 9 2010 129 140